Recently, a new medication has been added to our armorantarium to combat exudative age related macular degeneration, known as Eylea or VEGF-TRAP. The safety and effectiveness of Eylea was evaluated in two clinical trials involving 2,412 adult patients. People in the study received either Eylea or Lucentis. Eylea was injected into the eye either every four weeks for the first three months and then every eight weeks thereafter. The studies showed that Eylea was as effective as Lucentis in maintaining or improving visual acuity in patients with exudative age related macular degeneration and can be a treatment option for patients.